Francesco Massari
University of Massachusetts Medical School
CancerInternal medicineRadiologySurgeryPathologyOncologyCardiologyRetrospective cohort studyRenal cell carcinomaCarcinomaImmunotherapyDiseaseSunitinibProstate cancerBladder cancerIn patientCancer researchClinical trialMedicineBiology
502Publications
41H-index
5,976Citations
Publications 470
Newest
IntroductionWhile sorafenib monotherapy represented the mainstay of medical treatment for advanced hepatocellular carcinoma (HCC) patients for more than a decade, novel agents and combination thera...
Source
OBJECTIVE Recent years have registered the advent of novel treatment options for metastatic renal cell carcinoma (mRCC), including combination therapies with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). Immuno-TKI combinations have been suggested to improve clinical outcomes but may also result in increased toxicity, including gastrointestinal (GI) adverse events. METHODS Herein, we performed a meta-analysis aimed at comparing the risk of certain GI toxicities in mR...
Source
#1Marwa Elnazeir (UMMS: University of Massachusetts Medical School)
#2Lisa Nobel (UMMS: University of Massachusetts Medical School)H-Index: 4
Last. Adalia Jun-O 'Connell (UMMS: University of Massachusetts Medical School)
view all 8 authors...
Source
Non-clear cell renal cell carcinomas are a miscellaneous group of tumors that include different histological subtypes, each one characterized by peculiarity in terms of genetic alteration, clinical behavior, prognosis, and treatment response. Because of their low incidence and poor enrollment in clinical trials, alongside their heterogeneity, additional efforts are required to better unveil the pathogenetic mechanisms and, consequently, to improve the treatment algorithm. Nowadays, tyrosine kina...
Source
#1Umberto BassoH-Index: 39
#2Antonella Facchinetti (UNIPD: University of Padua)H-Index: 10
Last. Vittorina ZagonelH-Index: 68
view all 23 authors...
BACKGROUND Circulating Tumor Cells (CTCs) correlate with adverse prognosis in breast, colorectal, lung and prostate cancer patients. Little data is available for Renal Cell Carcinoma (RCC). MATERIALS AND METHODS We designed a multicenter prospective observational study to assess the correlation between CTC counts and Progression Free Survival (PFS) in metastatic RCC patients treated with an anti-angiogenic tyrosine kinase inhibitor as a first-line regimen; Overall Survival (OS) and response were...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 13
Last. Francesco MassariH-Index: 41
view all 3 authors...
Source
#1Pietro Scicchitano (University of Bari)H-Index: 28
#2Marco Tucci (University of Bari)H-Index: 33
Last. Marco Matteo Ciccone (University of Bari)H-Index: 33
view all 10 authors...
The need for anticoagulation in patients with atrial fibrillation (AF) is fundamental to prevent thromboembolic events. Direct oral anticoagulants (DOACs) recently demonstrated to be superior, or at least equal, to Warfarin in reducing the risk for stroke/systemic embolism and preventing major bleeding and intracranial hemorrhages. The AF population often suffers from chronic kidney disease (CKD). Indeed, the relationship between AF and renal function is bidirectional: AF can trigger kidney fail...
3 CitationsSource
INTRODUCTION Substantial paradigm shifts have been recently registered in metastatic renal cell carcinoma (mRCC), with combination therapies including immunotherapy showing unprecedented results. We performed number needed to treat (NNT) and number needed to harm (NNH) analyses to evaluate these approaches in mRCC. AREAS COVERED Clinical data of mRCC patients enrolled in four phase III trials were collected. The rates at 6, 12, 18, and 24 months for overall survival (OS), duration of response (D...
Source
#1Alessia Cimadamore (Marche Polytechnic University)H-Index: 17
#2Liang Cheng (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 132
Last. Rodolfo Montironi (Marche Polytechnic University)H-Index: 96
view all 10 authors...
Approximately 23% of metastatic castration-resistant prostate cancers (mCRPC) harbor deleterious aberrations in DNA repair genes. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) therapy has shown improvements in overall survival in patients with mCRPC who harbor somatic and/or germline alterations of homology recombination repair (HRR) genes. Peripheral blood samples are typically used for the germline mutation analysis test using the DNA extracted from peripheral blood leucocytes. Somati...
Source
Source